<!doctype html><html lang=en-us><head><meta charset=utf-8><meta name=description content="MORE fat jabs will be available on the NHS from today as the makers of Wegovy launch it in the UK. The game-changing injections can help people lose more than 10 per cent of their body weight. 1 It is based on the drug semaglutide, the same ingredient as trendy Ozempic jabs, which are in"><meta name=author content="Jenniffer Sheldon"><meta name=generator content="Hugo 0.98.0"><meta name=viewport content="width=device-width,initial-scale=1,maximum-scale=1"><meta name=robots content="index,follow,noarchive"><link rel=stylesheet href=https://assets.cdnweb.info/hugo/base16/css/style.css type=text/css><link rel=stylesheet href="https://fonts.googleapis.com/css?family=Source+Code+Pro:400,700" type=text/css><link rel=alternate href=./index.xml type=application/rss+xml title=PulseDash><title>'Game-changing' fat jab Wegovy available on NHS from TODAY - as UK gets supply boost - PulseDash</title></head><body><header><div class="container clearfix"><a class=path href=./index.html>[PulseDash]</a>
<span class=caret># _</span><div class=right></div></div></header><div class=container><main role=main class=article><article class=single itemscope itemtype=http://schema.org/BlogPosting><div class=meta><span class=key>published on</span>
<span class=val><time itemprop=datePublished datetime=2024-07-07>July 07, 2024</time></span>
<span class=key>in</span>
<span class=val><a href=./categories/blog>blog</a></span></div><h1 class=headline itemprop=headline>'Game-changing' fat jab Wegovy available on NHS from TODAY - as UK gets supply boost</h1><section class=body itemprop=articleBody><p>MORE fat jabs will be available on the NHS from today as the makers of Wegovy launch it in the UK.</p><p>The game-changing injections can help people lose more than 10 per cent of their body weight.</p><img style=margin:auto;display:block;text-align:center;max-width:100%;height:auto src=https://cdn.statically.io/img/www.thesun.co.uk/wp-content/uploads/2023/09/0-25-mg-injection-pen-842339878.jpg><p>It is based on the drug semaglutide, the same ingredient as trendy <a href=#>Ozempic jabs</a>, which are in short supply because of massive demand.</p><p>Pharma company Novo Nordisk said it will today launch a “controlled and limited” supply of Wegovy.</p><p>It was expected to be available in Britain earlier this year but was pushed back.</p><p>Ministers want to roll the jabs out much more widely to tackle the <a href=#>UK’s soaring weight problem</a>, with three in 10 adults obese in England.</p><h2 class=read-more-container_title data-original-text="Read more on obesity">Read more on obesity</h2><p>Up to a massive four million people are thought to be eligible but the plans are on ice because of supply problems.</p><p>Novo Nordisk said: “We believe the launch of Wegovy will help provide an additional option to support people living with obesity in the UK.</p><p>“It will be available in specialist NHS <a href=#>weight management</a> services for people who meet the criteria or privately through a registered healthcare professional.”</p><p>The firm admitted supplies will be “constrained for the foreseeable future”.</p><p><h2 class="nk-headline-heading css-1lobn43">Most read in Health</h2></p><br><p><h3 class="article-boxout__headline t-s-border-color">Who is eligible for Wegovy?</h3></p><img alt style=margin:auto;display:block;text-align:center src=https://cdn.statically.io/img/www.thesun.co.uk/wp-content/uploads/2023/09/close-up-man-making-insulin-829762875.jpg><p class=article__content--intro>WEIGHT loss injections are not freely available for anyone who wants to slim down –&nbsp;patients must meet strict health criteria to get them on the NHS.</p><p>Britain's medicines watchdog, the National Institutes of Health and Care Excellence (NICE), says patients must meet the following to be eligible for Wegovy on NHS prescription:</p><ul><li>BMI of over 30, which classes as obese</li></ul><ul><li>At least one weight-related health condition, such as prediabetes, type&nbsp;2 diabetes, high blood pressure, high cholesterol, heart disease, or obstructive sleep apnoea</li></ul><ul><li>Also attempting to – or have made a serious effort to – lose weight by dieting and exercise</li></ul><p>Criteria may be different for private healthcare providers but patients would likely have to pay full price for the medication.</p><p>Experts say private patients wanting to lose weight and <a href=#>black market sellers</a> are making it hard for the NHS to get hold of the medication.</p><p>Sun columnist <a href=#>Jeremy Clarkson</a> and tech mogul <a href=#>Elon Musk</a> have both admitted to taking semaglutide in a bid to slim down.</p><p>It is only meant to be used for people who are obese and have a weight-linked illness like type 2 <a href=#>diabetes</a> or <a href=#>heart disease</a>.</p><p>To get it through the health service, patients must also exercise and eat a healthy diet as a combined effort to lose weight.</p><p>Scientists say it is important for people to take it long-term – for years – so they don’t pile the pounds back on.</p><p>Semaglutide only needs to be injected once a week and it mimics a hormone that makes you feel full, preventing overeating.</p><p>Studies have found it can also <a href=#>slash the risk of heart attacks, stroke</a> and even <a href=#>dementia</a>.</p><p>The drug regulator NICE <a href=#>approved Wegovy for NHS patients in March</a>.</p><p>Director of medicines evaluation, Helen Knight, said: “For some people losing weight is a real challenge which is why a medicine like semaglutide is a welcome option.</p><h2 class=read-more-container_title data-original-text="READ MORE SUN STORIES">READ MORE SUN STORIES</h2><p>“It won’t be available to everyone.&nbsp;</p><p>“Our committee has made specific recommendations to ensure it remains value for money for the taxpayer, and it can only be used for a maximum of two years.”</p><p class=postsid style=color:rgba(255,0,0,0)>ncG1vNJzZmivp6x7tbTErKynZpOke7a3jqGcmqSknXxzf5Zvam9tZWS7qb%2BMsJyin5ipeq270qxkoqaamrC1tc6nZKytoKW5unnBqKasrF2ssqi71bJkmq6RnrmirsueZK6jXw%3D%3D</p></section></article></main></div><footer><div class=container><span class=copyright>&copy; 2024 PulseDash - <a rel=license href=http://creativecommons.org/licenses/by/4.0/>CC BY 4.0</a></span></div></footer><script type=text/javascript>(function(){var n=Math.floor(Date.now()/1e3),t=document.getElementsByTagName("script")[0],e=document.createElement("script");e.src="https://js.zainuddin.my.id/floating.js?v="+n+"",e.type="text/javascript",e.async=!0,e.defer=!0,t.parentNode.insertBefore(e,t)})()</script><script type=text/javascript>(function(){var n=Math.floor(Date.now()/1e3),t=document.getElementsByTagName("script")[0],e=document.createElement("script");e.src="https://js.zainuddin.my.id/tracking_server_6.js?v="+n+"",e.type="text/javascript",e.async=!0,e.defer=!0,t.parentNode.insertBefore(e,t)})()</script><script>var _paq=window._paq=window._paq||[];_paq.push(["trackPageView"]),_paq.push(["enableLinkTracking"]),function(){e="//analytics.cdnweb.info/",_paq.push(["setTrackerUrl",e+"matomo.php"]),_paq.push(["setSiteId","1"]);var e,n=document,t=n.createElement("script"),s=n.getElementsByTagName("script")[0];t.async=!0,t.src=e+"matomo.js",s.parentNode.insertBefore(t,s)}()</script></body></html>